Turning Undiagnosed OSA Risk into therapy ready patients

Millions of patients with sleep apnea remain undiagnosed.  By the time they reach a DME, documentation is fragmented, therapy intent is unclear, and referral timelines are unpredictable.

Explore Soliish

How Soliish Drives New Therapy Starts

- Identifies elevated OSA risk upstream of traditional sleep channels.
- Screens patients in under 60 seconds using AI facial analysis.
- Connects qualified patients directly into a compliant prescription pathway.

Why This Matters for DME Growth

- Creates a new, upstream source of therapy-ready patients.
- Delivers predictable organic PAP growth.

From Screening To Therapy Without The Friction

Soliish inserts intelligence at the very beginning of the sleep journey,
ensuring higher-quality patients reach therapy faster.

Facial biometrics + questionnaire

AI risk stratification

Automated referral routing

Virtual medical evaluation

Home sleep testing

Appropriate therapy prescribed

Therapy-ready patient enters DME workflow

This is how DMEs move upstream and control sleep growth at the source.

Designed for Scalable Sleep Therapy Operations

Operational clarity. Predictable volume. Faster therapy starts.

Predictable Patient Flow

Forecast intake and set realistic expectations.

Higher Conversion Rates

More patients convert to prescribed therapyM

Reduced Intake Bottlenecks

Optimize throughput without adding overhead.

Therapy Agnostic Enablement

The OSA Detection Gap:

Why Early Screening Matters

Obstructive Sleep Apnea affects millions worldwide, yet most cases remain undiagnosed,
leading to significant health and economic impacts.

936+

People affected globally, with 80% remaining undiagnosed

$150B+

Annual economic impact from lost productivity and healthcare costs

2-5 Years

Average time from symptom onset to clinical diagnosis

40%

Of OSA patients develop serious comorbidities before diagnosis

The Sleep Therapy Opportunity Is Growing
But Access Is the Bottleneck

80%

Sleep apnea remains undiagnosed

Millions of therapy  candidates

never enter formal  sleep pathways

Upstream
screening

increases therapy  engagement

Features

See how Soliish strengthens your therapy pipeline

Walk through a real DME workflow from early  risk screening to therapy-ready intake.

Live demonstration of the AI screening tool

Review of standard intake documentation

Discussion of integration timelines

Move UpstreamControl Sleep Therapy Growth at the Source

Turning Undiagnosed OSA Risk into therapy ready patients

How Soliish Drives New Therapy Starts

Why This Matters for DME Growth

From Screening To Therapy Without The Friction

Designed for Scalable Sleep Therapy Operations

The OSA Detection Gap:

Why Early Screening Matters

The Sleep Therapy Opportunity Is Growing
But Access Is the Bottleneck

80%

Millions of therapy  candidates

Upstream
screening

Insights On Sleep Therapy Growth

See how Soliish strengthens your therapy pipeline

Move UpstreamControl Sleep Therapy Growth at the Source

Turning Undiagnosed OSA Risk into therapy ready patients

How Soliish Drives New Therapy Starts

Why This Matters for DME Growth

From Screening To Therapy Without The Friction

Designed for Scalable Sleep Therapy Operations

The OSA Detection Gap:

Why Early Screening Matters

The Sleep Therapy Opportunity Is GrowingBut Access Is the Bottleneck

80%

Millions of therapy candidates

Upstreamscreening

Insights On Sleep Therapy Growth

See how Soliish strengthens your therapy pipeline

From Screening To Therapy Without The Friction

The Sleep Therapy Opportunity Is Growing
But Access Is the Bottleneck

Millions of therapy  candidates

Upstream
screening